This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Law Offices Of Todd M. Garber Announces Investigation Of Vanda Pharmaceuticals, Inc.

The Law Offices of Todd M. Garber announces that it is investigating potential claims against Vanda Pharmaceuticals, Inc. (“Vanda” or the “Company”) (NASDAQ:VNDA) concerning possible violations of federal securities laws. The investigation focuses on certain statements issued by Vanda between December 18, 2012 and June 18, 2013 regarding the Company’s business and financial prospects.

Vanda is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders. The Company’s product tasimelteon -- a treatment for circadian rhythm sleep disorders (CRSD) -- is currently in clinical development for a serious, rare CRSD known as “Non-24.” The investigation concerns allegations that the Company issued false and misleading statements or failed to disclose material adverse facts concerning the Phase III clinical trials for tasimelteon, including (1) whether the primary endpoint installed to assess tasimelteon’s efficacy and safety was replaced by the Company with an endpoint that was not endorsed by the Food and Drug Administration and had never been used before in sleep-drug clinical trials, and (2) whether tasimelteon demonstrated any discernible difference in efficacy and safety in nighttime total sleep between those patients deemed to have Non-24 and those patients with a normal circadian rhythm.

If you purchased Vanda stock during the foregoing period, if you have information or would like to learn more about these claims, or if you purchased Vanda shares prior to December 18, 2012 and wish to discuss these matters, please contact Todd M. Garber, Esquire, of the Law Offices of Todd M. Garber, by telephone at 213-700-7262 or by email to

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs